AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie’s executives, perhaps guided by previously slow biosimilar adoption in Europe, have forecast a drop of Humira sales in Europe of only around 18 to 20%, by the end of next year.

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

But until then AbbVie has been making the most of Humira’s dominant position in the US inflammatory disease market, with sales increasing nearly 7% in Q1 to more than $3.9 billion.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...